“AlzeCure Pharma stock surges 301% on Eli Lilly deal.”
AlzeCure Pharma (ST:ALZCUR) shares soared 301% on Tuesday following the announcement of a collaboration and out-licensing agreement with Eli Lilly and Company (NYSE:LLY) for its Alzheimer’s project Alzstatin ACD680.
The Swedish biotech company will receive an upfront payment of $10 million, along with development and commercial milestones, and tiered mid-single-digit royalties on sales. The total deal value, excluding royalty payments, may exceed $1 billion.